GenWay Biotech Adds Thomas Silberg To Team As New President and CEO

Share Article

Thomas Silberg contributes strong leadership and experience to advance GenWay's presence in the diagnostic field. A new marketing strategy and business plan will be implemented for the proactive testing solutions offered by GenWay's CLIA laboratory.

“We are pleased to have the addition of such a seasoned individual to the team."

GenWay Biotech, Inc., a US-based diagnostic company is pleased to announce that Thomas Silberg has joined the company as the new President and CEO. GenWay hopes to capitalize on his impressive track-record and experience in leading numerous pharmaceutical and biotech companies, through periods of growth, mergers and product launches. Mr. Silberg has over thirty-eight years of experience working with and leading pharmaceutical companies such as Hoffmann-La Roche, Ligand Pharmaceuticals, Abraxis Bioscience, and APP Pharmaceuticals.

In Mr. Silberg’s most recent position, at APP Pharmaceuticals, he led the execution of a business plan which resulted in growing the company over a short period of four years into the second leading U.S. company for generic injectables. At GenWay, Mr. Silberg will utilize his expertise to implement a similar strategy to foster the growth of the diagnostic division which currently offers a proactive diagnostic testing solution for cancer. GenWay will be launching its cardiovascular assessment panel in early 2011. Mr. Silberg will also assist with leading the catalog and custom service divisions which have steadily grown over recent years.

Robert Gans, Executive President and CFO of GenWay Biotech, said “We are pleased to have the addition of such a seasoned individual to the team. We look forward to benefiting from Tom’s strong experience and leadership. Based on his successful track-record of driving marketing, sales activities and eventually revenues, we feel he can contribute significantly towards the advancement of GenWay Biotech’s presence in the diagnostic field.”

Mr. Silberg has been an active member of GenWay’s Board of Directors since July 2010 and is also a member of numerous other boards, including the Generic Pharmaceutical Manufacturers Association (GPhA). GenWay feels that the addition of Mr. Silberg to the leadership team will strengthen their position to excel in the diagnostic field as a leader of proactive testing solutions.

About GenWay:
GenWay Biotech, Inc. is a biotechnology company based in San Diego, CA that manufactures and supplies reagents such as antibodies and antigens, and products that aid in the early detection and monitoring of various diseases. The Company's proprietary technology platform specializes in producing avian IgY antibodies from proteins of human, animal, plant, bacterial and other sources. GenWay also offers single chain recombinant scFv and shark vNAR antibody technologies. More than 50,000 products are available from the Company's catalog. GenWay is also actively developing novel diagnostic tests in the field of cardiovascular and sexually transmitted disease diagnostics.

For more information about the Company’s lead product in the diagnostic field, the You Test You Cancer Assessment, please visit or contact Dr. Jill Dombrauckas, jdom(at)genwaybio(dot)com, (858)458-0866 x119.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jill Dombrauckas, PhD
GenWay Biotech, Inc.
858-458-0866 ext. 119
Email >
Visit website